Silence Therapeutics said this week that it has received a notice of allowance from the US Patent and Trademark Office on a patent application covering its siRNA delivery technology.
According to Silence, the allowed claims relate to the company's AtuPlex technology. Specifically, they cover the proprietary lipid used in the delivery system. The company noted that the technology is being used in its phase I cancer drug Atu027, as well as certain other RNAi drug candidates.